ClinicalTrials.gg
Status unknownNCT04055831Updated Aug 15, 2019

Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease

An observational study in Gaucher Disease Type 1, sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc.. Status unknown at 1 site in United States. Open to participants aged 16 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-15.

Sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
16 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.

Planned enrollment
25th of 39
40 · median 60
Started
2019
with 5 others
Observational
39 of 92
16 open now
Registered
64th of 92
by date
Lead sponsor
5 of 92
Lysosomal and Rare Disorders Research and Treatment Center, Inc.

Among the 92 studies in Gaucher Disease with a site in United States, this one is the 25th largest by planned enrollment of the 39 observational ones that give a count, is one of 6 that started in 2019, is one of 39 observational ones, and was the 64th registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 16 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Gaucher Disease with a site in United States, or all of them as a file.
02

Study summary

Bone-related problems represent the principal unmet medical need in Gaucher disease (GD). 75% of GD type 1 patients develop skeletal complications, including bone remodeling defects, osteopenia, osteoporosis, marrow infiltration, avascular necrosis, and osteolysis. However, the underlying cellular/molecular basis of bone involvement and related complications in GD are not fully known. Neither are there any bone-specific markers associated with individual bone pathology. Early diagnosis of bone disease is the key issue for planning individual therapy to prevent and reverse bone disease in GD.

Read the detailed description

This clinical observational study is designed to identify specific biomarkers for bone involvement in patients with GD1 with decreased bone density and/or bone structural abnormalities

Aims:

  1. Identify novel immune cell surface and biochemical markers in peripheral blood correlating with bone involvement in GD.
  2. Assess the correlation between cytokine levels in peripheral blood and the severity of bone involvement in GD.
  3. Assess the relationship between glycosphingolipids accumulation and macrophage activation with specific bone markers and GD severity.
03

Conditions studied

  • Gaucher Disease Type 1

Keywords

  • Gaucher disease
  • Osteoporosis
04

Who can participate

Ages eligible
16 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Clinically confirmed GD1 patients will be stratified based on their disease severity and bone density findings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be enrolled in this study the subject must meet the following criteria

    1. Subject is greater than 16 years old but not older than 90 years
    2. Signed /Assent
    3. Subject is able and willing to sign informed consent or assent
    4. If the subject has GD1, the must have a confirmed diagnosis of Gaucher disease by

      • GCase enzyme activity
      • DNA analysis demonstrating pathogenic variants in the GBA gene

Exclusion criteria

Exclusion Criteria:

  • a) Have evidence of , infection or any other chronic infectious disease b) Be pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • GD1 subjects with no bone complications

    1. GD1 subjects with no bone complications (n=10)

  • GD1 patients with mild bone complication

    2. GD1 subjects with mild bone complications

  • GD1 with severe bone complications

    3. GD1 subjects with severe bone complications

  • No bone disease

    Controls with no known bone disease (n=10)

06

What researchers measure

Primary outcomes

  1. Measure biomarkers level in molar/l/h

    Bone homeostasis is dependent on the balance of deposition by osteoblasts DMP-1, OSCAR, Calcitonin, Lyso-GB1, chitotriosidase, CCL18, osteocalcin, BALP, cathepsin K , TRAP 5, RANKL, OPG, DDK-1, sclerostin, MCP1, IL-2, IL-6, IL-10, SRTH2 and TNF-α

    Time frame: 18 months

  2. Measure biomarkers level: molar/mg/h

    DMP-1, RANK, OSCAR, cathepsin K, OPG

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
  • LDRTC
    Fairfax, Virginia 22030, United States
    Recruiting
    • Ozlem Goker-Alpan, MD · Contactogokar-alpan@ldrtc.org · 703-261-6220
    • Margarita M Ivanova, PhD · Contactmivanova@ldrtc.org · 7032616220
    • Ozlem Goker-Alpan, MD · Principal investigator
    • Margarita Ivanova, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2019 (actual). Primary completion is estimated for Apr 2020, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2019
First posted
Aug 14, 2019
StartActual
May 15, 2019
Primary completionEst.
Apr 15, 2020
CompletionEst.
May 15, 2020
Last update
Aug 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04055831
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Responsible party
Sponsor
First posted
Aug 14, 2019
Start date
May 15, 2019
Primary completion
Apr 15, 2020 (estimated)
Completion
May 15, 2020 (estimated)
Last update
Aug 15, 2019

Study contacts

Jacqueline Fikry
Contact
jfikry@ldrtc.org
571-732-4575
Margarita Ivanova, PhD
Contact
mivanova@ldrtc.org
5715296724
Ozlem Goker-Alpan, MD
principal investigator · Lysosomal and Rare Disorders Research and Treatment Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion